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1. Introduction 
Over the last decade, since the development of improved systemic agents for colorectal cancer, 
there has been increasing exploration of the use of neoadjuvant strategies for colorectal liver 
metastases (CRLM). In some cases, upfront chemotherapy enables downsizing, in order to 
enhance resectability. In other cases, neoadjuvant chemotherapy is a means to expedite 
delivery of systemic therapy and perhaps also to select patients for subsequent treatments. 
2. Surgical management of colorectal liver metastases 
Since the 1980s, hepatectomy has been increasingly performed for patients with liver-only 
metastases from colorectal cancer. The first large series were published in the 1990s, 
demonstrating 5-year survival of 25-40% for patients who underwent R0 resections. These 
compared favorably with the 0-5% survival rates for patients with technically resectable 
disease who did not undergo resection, or who had positive margins at resection (R1 or R2) 
(Scheele & Altendorf-Hofmann, 1999). The patients included in these early series where a 
highly select group, mostly with solitary lesions less than 5 cm in diameter. However, from 
these data the initial guiding principles of surgery for CRLM were developed: a) exclusion 
of patients with any extra-hepatic metastases; b) removal of all detectable liver metastases 
while providing sufficient residual liver volume for postoperative function; and c) 
achievement of negative margins (R0 resection; Fong et al., 1997). 
With advancements in preoperative staging, surgical techniques, and multimodality treatment 
since that time, this definition of resectability has been greatly expanded. Current approaches 
extend the possibility of surgical resection to patients with CRLM involving: both lobes of the 
liver; large/multiple lesions requiring extended hepatectomies; and extra-hepatic sites, 
particularly pulmonary (Yang et al., 2010). For practical purposes, the only remaining limits on 
the definition of “resectable” are the achievement of negative margins, preservation of 
adequate remnant liver (minimum 20% with a healthy liver) with vascular and biliary 
inflow/outflow, and capacity of the patient to tolerate the planned, often multimodality, 
treatment (Charnsangavej et al., 2006; Nordlinger et al., 2009).  
Even with these expanded resection criteria and increasingly aggressive surgical strategies, 
survival rates have continued to improve. Recent large series report 5-year overall survival 
of 53 - 58% and 5-year recurrence-free survival of 28 - 36% (Abdalla et al., 2004; Choti et al., 
2002; Fernandez et al., 2004; Figueras et al., 2001; Pawlik et al., 2005). These series are 
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predominantly from highly specialized institutions. Studies of national administrative 
databases, over the same time period, report a more modest 5-year overall survival of 22 - 
33% following hepatectomy (Cummings et al., 2007; Robertson et al., 2009; Wang et al., 
2007). In all studies, whether single centre or population based, the great majority of patients 
undergoing surgery also received preoperative and/or postoperative chemotherapy. The 
integration of medical and surgical therapies, with advances in each, and improvements in 
our ability to effectively and safely combine modalities, has undoubtedly contributed to the 
observed improvement, or at least stability, of survival rates despite the inclusion of patients 
with increasingly advanced disease.  
Although the presence of extra-hepatic metastases continues to be associated with worse 
overall survival, aggressive multi-site resection strategies, in combination with 
chemotherapy, have achieved 5-year survival rates of 19 - 28% at specialty centres (Adam et 
al., 2011; Carpizo & D'Angelica, 2009; Figueras et al., 2007). Surgical candidates with multi-
site metastases are often treated with several cycles of chemotherapy and then resected, 
often with multiple operations, if they show stable or responsive disease. Those with only 
pulmonary extra-hepatic metastases are the most commonly treated in this fashion but 
emerging data suggests that indicators of tumor biology and total number of metastatic sites 
are stronger predictors of survival than the actual sites of metastatic disease, assuming that 
complete resection can be achieved (Adam et al., 2011). 
Prior to resection of liver metastases, patients undergo detailed radiographic examination of 
the liver by either CT or MRI. In many centres, PET-CT imaging is obtained on all patients 
with potentially resectable liver lesions. The addition of PET imaging has been shown to 
alter management in 10-30% of patients, usually by the detection of previously unknown 
extra-hepatic lesions (Charnsangavej et al., 2006). With all types of imaging, evaluation by 
an experienced hepatobiliary radiologist is an important part of surgical, chemotherapeutic, 
and other treatment planning.  
Patients with synchronous liver metastases at the time of their primary tumor diagnosis 
require individualized decision-making regarding surgery and any neoadjuvant 
chemotherapy. In the case of an obstructing primary tumor or a patient with significant 
anemia, a surgical approach to address the primary tumour is usually required prior to 
consideration of chemotherapy and/or resection of CRLM. In asymptomatic patients, staged 
or combined resections of the primary and metastatic lesions can be considered, with similar 
perioperative outcomes and survival in large retrospective series (de Haas et al., 2010; Lyass et 
al., 2001; Martin et al., 2009). One clinical trial is currently accruing patients in an attempt to 
address this question prospectively (Rennes University Hospital, 2009). Decision-making 
regarding the surgical approach depends on the complexity of each part of the surgery, the 
surgeons’ experience, the patient’s ability to tolerate lengthy and complex surgery, and 
logistical factors (Charnsangavej et al., 2006). Neoadjuvant chemotherapy is now frequently 
offered to these patients. Overall, survival appears to be similar between the various 
approaches, although no prospective trials have considered this question (Brouquet et al., 2010). 
In patients with bilobar CRLM or in whom resection of all lesions would leave an 
insufficient future liver remnant (FLR), several surgical and interventional techniques are 
available to convert the patient to a resectable state. Hypertrophy of the FLR can be achieved 
by ligating or embolizing the portal vein feeding the diseased lobe(s) of the liver (Figure 1). 
If on repeat imaging, 4 - 6 weeks following portal vein embolization (PVE), the FLR has 
adequately hypertrophied, patients can undergo extended hepatectomy with perioperative  
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Fig. 1. Portal vein embolization is used to induce hypertrophy of the liver remnant. The lobe 
or segments containing the liver metastases (and to be resected) is embolized, if it is 
anticipated that the remaining liver will be too small to provide adequate functional hepatic 
reserve (A, B). After 4 – 6 weeks, the non-embolized segments of liver will hypertrophy (C), 
allowing an extensive liver resection with a greater margin of safety. 
A 
C 
B 
www.intechopen.com
 
Neoadjuvant Chemotherapy – Current Applications in Clinical Practice 
 
160 
outcomes and long-term survival similar to that in patients who did not require PVE (Abdalla 
et al., 2006; Yang et al., 2010). One contraindication to PVE is the presence of lesion(s) in the 
FLR, due to the risk of progression with hypertrophy. In these cases, a staged approach to 
resection may be possible. At the initial operation, the lesion(s) in the FLR are resected and the 
portal vein to the remainder of the diseased liver is ligated. If the patient recovers well and 
sufficient hypertrophy is achieved, a second laparotomy with extended hepatectomy is 
undertaken 6 - 12 weeks later. Perioperative morbidity and long-term survival with this 
approach appears to be similar to that of patients with a similar burden of disease who achieve 
complete resection with a single hepatectomy (Chun et al., 2007; Wicherts et al., 2008; Yang et 
al., 2010). The administration of chemotherapy has been successfully implemented with all of 
these approaches – preoperatively, between staged operations, and postoperatively. The 
relative contribution of surgical and chemotherapeutic components of these complex 
management algorithms is unknown. However, as in the more straightforward clinical 
scenarios discussed in detail below, any evidence of disease progression while on 
chemotherapy is usually cause for re-evaluation of any further surgical intervention. 
When complete surgical resection cannot be achieved, even with the use of adjuncts such as 
PVE and staged hepatectomies, radiofrequency ablation (RFA) can be used in conjunction 
with hepatectomy. When compared head-to-head for single lesions, RFA has a significantly 
higher recurrence rate and is inferior to resection (Aloia et al., 2006a). However, in the era of 
modern chemotherapy, patients with multiple lesions treated with a combination of 
resection and RFA, long-term survival rates similar to those of patients with complete 
resection have been achieved (Nikfarjam et al., 2009). This suggests that in patients with 
CRLM that are stable or regressing on chemotherapy, but which remain technically 
unresectable, an approach that includes resection and RFA may be considered. 
The final surgical scenario worth noting in the context of CRLM is the patient with 
synchronous disease who stabilizes or responds to neoadjuvant chemotherapy but whose liver 
disease remains unresectable. These patients may have an extended survival and the question 
often arises whether there is value in resecting their primary lesion. Data supporting a survival 
benefit from such a resection come from series that pre-date modern chemotherapy (Cook et 
al., 2005; Ruo et al., 2003). With the prolonged survival offered by current chemotherapy 
regimens, any added benefit is more likely to be related to prevention of local morbidity. The 
likelihood of developing obstruction and/or pain from local invasion appears to be greatest in 
patients with rectosigmoid lesions. Therefore, prophylactic resection, particularly when it can 
be achieved with minimal morbidity, is likely of benefit in this group of patients (Scheer et al., 
2008). In all others, the chance of requiring emergent palliative surgery appears to be minimal 
and decisions regarding resection are made on an individual basis (Cellini et al., 2010). 
In general, the surgical management of CRLM is becoming more complicated and more 
aggressive. Partly, this is due to technical advances in hepatobiliary surgery. Perhaps of 
greater import is the development of newer systemic agents with greater activity against 
metastatic colorectal cancer.  
3. Systemic agents used for metastatic colorectal cancer 
Modern chemotherapy for metastatic colorectal cancer is typically a multi-drug regimen. 
Doublet regimens of a fluoropyrimidine combined with either oxaliplatin or irinotecan are 
highly effective in metastatic and adjuvant colorectal cancer. The addition of a targeted 
biologic agent further increases response rates in appropriate metastatic patients (Compton 
et al., 2008; Douillard et al., 2010; Folprecht et al, 2010).  
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Fluorouracil is a pyrimidine analog developed in the 1950s. It functions to interrupt DNA 
synthesis by inhibiting DNA methylation. Fluorouracil can be given in an intravenous form, 
5-FU, or orally via capecitabine, which is subsequently metabolized to an active molecule. 
When given in IV formulation, fluorouracil is commonly combined with the folate 
derivative, leucovorin, to enhance its function. 
Irinotecan (also known as CPT-11) was approved for use in metastatic colorectal cancer in 
the mid-1990s. It is an inhibitor of topoisomerase I, a complex that reduces the torsional 
strain on DNA by breaking, detorting and reconnecting single strands of DNA. Irinotecan’s 
action on topoisomerase I allows single strand breaks to accumulate, ultimately leading to 
cell cycle arrest and cell death. 
Oxaliplatin was introduced to the global market in the late 1990s. It is a platinum-based 
compound that cross-links DNA, preventing its replication and transcription. The 5-FU, 
leucovorin, and oxaliplatin combination, FOLFOX, is highly effective in the metastatic 
setting, but its long-term use is limited by a cumulative dose-dependent side effect of 
peripheral sensory neuropathy. 
Novel biologic agents have been recently introduced into clinical use and are monoclonal 
antibodies to proteins key to tumor growth pathways. Bevacizumab is a fully humanized 
antibody against vascular endothelial growth factor (VEGF), and results in inhibition of 
tumor angiogenesis. Cetuximab and panitumumab are antibodies to the human epidermal 
growth factor receptor (EGFR; also called HER1). EGFR blockade inhibits cell growth and 
induces apoptosis. Mutations of the KRAS gene, downstream from EGFR, negate the 
potential effects of EGFR inhibitors, and so only patients with wild-type KRAS benefit from 
this treatment (Karapetis et al., 2008). These medications are generally well tolerated, 
although rare but concerning side effects have been documented (Table 1B). As all of these 
agents are new to clinical use, their side effect profiles are likely to be refined over time. 
 
 
Agent Fluorouracil Irinotecan Oxaliplatin 
Common 
Side  
Effects  
Nausea/Vomiting 
Diarrhea 
Stomatitis 
Hand-foot syndrome 
Bone marrow 
suppression 
Hyperbilirubinemia 
Nausea/Vomiting 
Diarrhea 
Abdominal pain 
Bone marrow suppression 
Hair loss 
Asthenia 
Nausea/Vomiting 
Diarrhea 
Peripheral sensory 
neuropathy 
Stomatitis 
Bone marrow suppression 
Rare  
Side 
Effects 
Cardiac complications 
Liver fibrosis/failure 
Colitis/ ileitis/ bowel 
perforation 
Thromboembolic events 
Liver impairment, 
including SOS 
Thromboembolic events 
Liver impairment, 
including CASH 
Table 1A. Side effects of cytotoxic agents used in metastatic colorectal cancer. 
An overview of the side effect profiles of each of these drugs is given in Table 1. Of 
particular interest is the potential of chemotherapy to induce specific liver toxicity in the 
setting of future liver surgery, discussed further below.  
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Agent Bevacizumab Cetuximab Panitumumab 
Common 
Side 
Effects 
Hypertension 
Bleeding 
Abdominal pain 
Asthenia 
Nausea/Vomiting 
Diarrhea/constipation 
Rash
Infusion/hypersensitivity 
reactions 
Headache 
Abdominal pain 
Nausea/vomiting 
Diarrhea/constipation 
Bone marrow suppression
Rash
Infusion/hypersensitivity 
reactions 
Abdominal pain 
Nausea/vomiting 
Diarrhea/constipation 
Asthenia 
Peripheral edema 
Rare 
Side 
Effects 
GI perforation
GI fistula 
Delayed wound healing
Congestive heart failure
Thromboembolism
Respiratory complications 
Cardiopulmonary Arrest 
 
Respiratory complications 
Table 1B. Side effects of biologic agents used in metastatic colorectal cancer. 
4. Rationale for neoadjuvant chemotherapy 
Neoadjuvant chemotherapy could be considered in instances where the CRLM are 
resectable, or when CRLM are not technically resectable. The rationale for giving upfront 
chemotherapy for each of these circumstances differs, which bears some discussion. 
4.1 Unresectable colorectal liver metastasis 
The utility of using chemotherapy to downstage CRLM which are unresectable to a resectable 
status was first described by Bismuth et al (1996). Since then, in the setting of unresectable 
CRLM, unless some adjunctive approach such as PVE or two-stage hepatectomy is considered, 
all patients with unresectable CRLM should be considered for chemotherapy. After detailed 
imaging, chemotherapy is administered for 2 - 6 cycles, and then repeat detailed imaging is 
performed to evaluate for response. Patients with a response significant enough to make them 
candidates for resection are then reconsidered for surgery. Patients whose liver lesions do not 
respond or progress on chemotherapy continue on palliative-intent chemotherapy, with 
consideration for second-line and/or clinical trial agents.  
This approach has several benefits. Firstly, it defines a group of responders whose tumor 
biology is more favorable, and in whom aggressive resection is most likely to be of benefit. 
Secondly, it provides an in vivo measurement of the effectiveness of the given chemotherapy 
regimen for a given patient. Depending on the response, decisions can then be made about 
continuing with the same agents or switching regimens – either as adjunctive therapy 
following surgery, or as palliative-intent chemotherapy when surgery is not possible. 
4.2 Resectable colorectal liver metastasis 
In patients with initially resectable CRLM, the decision to administer upfront chemotherapy 
is much more complicated. A neoadjuvant chemotherapy approach has some advantages. 
First, it allows the delivery of systemic treatment early in the patient’s treatment course. 
Occult or micrometastatic disease is treated before it becomes clinically visible, when the 
burden of disease is low. Neoadjuvant therapy further allows the patient to receive 
chemotherapy during optimal health, as undoubtedly some surgical patients will experience 
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morbidity that will delay or preclude the administration of cytotoxic drugs. Secondly, 
neoadjuvant chemotherapy allows the clinician to assess tumor biology. Response to 
chemotherapy can be measured on serial imaging. Progression of disease, whether in or 
outside the liver, indicates resistance to the chemotherapy regimen used and thus provides 
the opportunity to select an alternative combination that may be more effective. Progression 
of disease while on chemotherapy is an independent predictor of worse survival and liver 
surgery may not be beneficial in this population (Adam et al., 2004b). Thus, this information 
further aids in selection of appropriate liver surgery patients. 
There are also some disadvantages that accompany neoadjuvant chemotherapy for CRLM. 
First, current chemotherapy regimens have the potential for liver damage. This risk is 
mitigated by careful monitoring and by limited durations of pre-operative chemotherapy. 
Secondly, disease progression on chemotherapy may preclude some patients who were 
initial surgical candidates from liver resection. This has been a rare event in trials of 
neodjuvant chemotherapy, and likely portends a worse overall prognosis (Nordlinger et al., 
2008; Bathe et al., 2009). Thus, it may actually spare patients from surgery if they are 
unlikely to achieve a survival benefit. Finally, up-front chemotherapy may cause some 
tumors to disappear completely, making subsequent decision-making more difficult. These 
challenges are discussed in more detail in Section 5. 
5. Clinical trials 
5.1 The role of neoadjuvant chemotherapy in unresectable liver-only metastases 
Chemotherapy has long been used as the sole treatment modality for patients with CRLM, 
with the goal of palliation and the prolongation of life by a few months. With the finding 
that hepatectomy can lead to long-term survival in 30 - 40% of patients, this goal changed. In 
initially unresectable patients, chemotherapy is now used with the aim of downstaging 
lesions to the point of resectability. If this is not achievable, then the goal shifts towards 
more traditional palliative-intent treatment. 
Clinical trials in the setting of liver-only metastases have thus begun to focus on determining 
the optimal chemotherapy regimen, in terms of maximizing response and resection rates, and 
also in terms of minimizing perioperative morbidity associated with the effects of intensive 
preoperative chemotherapy. In early cohort and phase II studies of unresectable patients, 
treatment with 5-FU, leucovorin and oxaliplatin and/or irinotecan (FOLFOX/FOLFIRI) led to 
a measurable response rate of 59 - 72% and achievement of margin-negative resections in 12-
38% of patients (Giachetti et al., 1999; Adam et al., 2004a; Masi et al., 2009). In patients 
undergoing resection after downstaging, median survival from the start of chemotherapy was 
37 - 48 months, compared to 14 - 15 months in those who did not respond sufficiently to allow 
resection and/or were not candidates for resection following chemotherapy. These results 
were obtained with the administration of, on average, 10 - 12 cycles of chemotherapy over a 5 - 
6 month period. No perioperative deaths were reported in these studies, although Masi et al. 
(2009) reported a perioperative morbidity rate of 27% including 8% transient liver failure.  
Two phase II trials have evaluated tumor response and secondary resection rates with the 
addition of biologic agents to FOLFOX/FOLFIRI chemotherapy. In initially unresectable 
patients, Wong et al. (2011) reports an objective response rate of 40% and a margin-negative 
resection rate of 10% after administration of capecitabine, oxaliplatin, and bevacizumab 
(CAPOX+B). With only 12 months of follow-up reported, median survival times have not 
been reached in this study. Of note, patients in this study received a median of only 4 cycles 
of preoperative CAPOX+B and 2 patients who achieved a complete response did not 
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undergo resection. Bevacizumab was stopped, on average, 10 weeks prior to hepatectomy 
but a 4% rate of grade 2 or 3 intestinal perforation was reported. Overall, the perioperative 
morbidity rate was 28%, with no liver failure events reported.  
In the CELIM trial (Folprecht et al., 2011), patients with unresectable CRLM were 
randomized to cetuximab plus either FOLFOX or FOLFIRI. The objective response rate was 
62%, with a 70% response rate in the subset of patients who were K-ras wildtype - a known 
predictor of responsiveness to cetuximab. The overall margin-negative resection rate was 
34% and patients received a median of 8 treatment cycles over a 5-month period prior to 
surgery. Survival data have not yet been published. Perioperative mortality was 4% and 
major morbidities occurred in 35%. 
The addition of bevacizumab has not been conclusively shown to improve response rate or 
resectability rate, either in the phase II trial reviewed here or, as a secondary end-point in 
phase III trials (Saltz et al., 2008). On the other hand, the response rates reported in the CELIM 
trial are quite compelling reasons to consider cetuximab-containing regimens when attempting 
to downstage unresectable liver metastases, particularly in K-ras wildtype patients. 
With modern chemotherapeutic regimens, usually incorporating oxaliplatin or irinotecan 
and biologic agents, responses to chemotherapy are well over 50% (Folprecht et al., 2010; 
Gruenberger, 2008a, 2008b). Downstaging of initially unresectable disease to resectable 
disease occurs in 13 - 40% of patients with liver-only metastases who have received systemic 
chemotherapy (Table 2 and Table 3). Higher rates of conversion to resectability are generally 
reported in surgical series (Table 3). The wide range of incidences of conversion of 
unresectable liver metastases to a resectable status is partly a function of the variations in 
definitions of resectability among surgeons and other oncologic specialties. This 
phenomenon was well illustrated in the series by Folprecht et al. (2010).  
 
Reference Agents N RR (%)
Liver Resection 
(%) 
Levi et al., 1999 5-FU, LV, Oxaliplatin 90 66 34 
De Gramont et al., 2000 5-FU, LV, Oxaliplatin 210 54 7 
Giacchetti et al., 2000 5-FU, LV, Oxaliplatin 100 53 32 
Scheithauer et al., 2003 Capecitabine, Oxaliplatin 89 48 9 
Teufel et al., 2004 5-FU, LV, Irinotecan 35 31 9 
Tournigand et al., 2004 
FOLFIRI → FOLFOX 
FOLFOX → FOLFIRI 
109 
111 
56 
54 
9 
22 
Sorbye et al., 2004 5-FU, LV, Oxaliplatin 82 62 11 
Bajetta et al., 2004 Capecitabine, Irinotecan 140 46 6 
Cassidy et al., 2004 Capecitabine, Oxaliplatin 96 55 5 
Kohne et al., 2005 5-FU, LV, Irinotecan 214 62 7 
Falcone et al., 2007 
FOLFIRI 
FOLFOXIRI 
122 
122 
41 
66 
6 
15 
Tabernero et al., 2007 FOLFOX, Cetuximab 43 72 23 
Table 2. Incidence of successful hepatic metastasectomy in first-line chemotherapy trials. 
Overall, these experiences have served to make response and resection rates important end 
points in trials of new chemotherapeutic agents for CRLM. Downstaging unresectable liver-
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only disease followed by surgery is accompanied by reasonable perioperative complication 
rates and has become the accepted standard. 
 
Reference Agents N Liver Resection (%) 
Adam et al., 2001 Mostly oxaliplatin-based 701 13.5 
Rivoire et al., 2002 5-FU, LV, Oxaliplatin 131 44 
Moehler et al., 2003 5-FU, LV, Irinotecan 46 6.5 
Pozzo et al., 2004 5-FU, LV, Irinotecan 40 32.5 
Delaunoit et al., 2005 92% oxaliplatin-based 795 3.3 
Masi et al., 2006 FOLFOXIRI 74 26 
Folprecht et al., 2010 
FOLFIRI + cetuximab 
FOLFOX + cetuximab 
55 
56 
38 
40 
Table 3. Rates of successful liver resection in surgical series where neoadjuvant 
chemotherapy was used to downstage tumour bulk. 
5.2 The role of neoadjuvant chemotherapy in resectable colorectal liver metastases 
There are few clinical trials of neodjuvant chemotherapy in the upfront resectable setting. 
The EORTC 40983 trial provides the only level I evidence for its use (Nordlinger et al., 2008). 
This trial enrolled 364 patients with up to four colorectal liver metastases to receive 
perioperative chemotherapy and liver resection versus surgery alone. The chemotherapy 
consisted of 12 cycles of FOLFOX4, with half given pre-operatively and half post-
operatively. In the chemotherapy arm, 80 percent of patients completed the preoperative 
schedule and 70% completed the entire regimen. At the time of surgery, 3% had a complete 
response, 40% a partial response, and 38% stable disease. Only 8 patients had progression 
that precluded surgery. Ultimately, 3 year progression-free survival went from 28.1 months 
in the surgery arm to 35.4 months in the multimodality arm, for a hazard ratio of 0.79. Final 
analysis of overall survival is still pending. 
A similar trend has been seen in nonrandomized trials. Bathe et al. (2009) published a phase 
II trial of 5-FU, leucovorin, and irinotecan as pre-operative chemotherapy for patients with 
resectable liver metastases. The study enrolled 35 patients, of whom 76 percent had 
responsive or stable disease during chemotherapy. Thirty-one patients went to surgery, with 
30 patients having R0 resection. Post-operative chemotherapy was also delivered to 22 
patients. Median disease-free survival (DFS) was 23 months and 2 year DFS was 47 percent. 
The study was halted early due to a high rate of thromboembolic complications. Meanwhile, 
Watkins et al. (2010) employed a strategy of neoadjuvant capecitabine and oxaliplatin in a 
heterogeneous group of patients with stage IV colorectal cancer, among them 32 patients 
with resectable liver only disease. Liver resection was ultimately performed in 19 patients. 
Median overall survival in the entire group was 52.9 months. 
Reddy et al. (2009) published a multi-institutional study of patients undergoing surgery 
for initially resectable, synchronous colorectal liver metastasis. A variety of treatment 
regimens were used, including pre-operative chemotherapy, post-operative chemotherapy, 
pre- and post-operative treatment, and no chemotherapy. This study found post-operative 
treatment for six months or longer was associated with improved overall survival in the 
synchronous liver metastases setting. The heterogeneity of the treatment regimens in terms 
of timing relative to surgery, duration of therapy, and drugs used makes this analysis 
difficult to interpret. 
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A summary of randomized and observational studies of neoadjuvant chemotherapy was 
recently published (Chua et al., 2010). With a heterogeneous group of chemotherapy 
protocols and patients, they estimated an objective response rate of 64% (range 44 - 100%) 
and a median overall survival of 46 months (range 20-67 months).  
Alternative approaches to neoadjuvant chemotherapy are available. Portier et al. (1996) 
studied chemotherapy in the adjuvant setting with positive results. They randomized 173 
patients to surgery alone versus surgery with adjuvant 5-FU/leucovorin for six months. The 
5 year disease-free survival was 26.7% for the surgery alone arm and 33.5% for the 
combined treatment. Hepatic artery infusional chemotherapy has been advocated by some 
groups as well. Kemeny et al. (1999) randomized 156 patients undergoing liver resection to 
post-operative systemic 5-FU based chemotherapy versus 5-FU-based hepatic artery 
infusional chemotherapy along with systemic chemotherapy. The median survival was 59.3 
months in the systemic arm and 72.2 months in the combined arm. Two other trials have 
found similar results (Lygidakis et al., 2001; Kemeny et al., 2002). Despite promising results, 
this technique has not gained popularity. The technical difficulty and expertise needed to 
perform the procedure safely has limited its use to a few highly specialized cancer centres, 
and would pose difficulty in expanding its use to the extraordinary numbers of patients 
with colorectal cancer. 
6. Special problems related to neoadjuvant chemotherapy for colorectal liver 
metastases 
6.1 Hepatotoxicity 
As the administration of neoadjuvant chemotherapy has become more popular, reports 
have emerged that clearly demonstrate associated hepatotoxicity, which may adversely 
affect operative outcomes. The type of hepatic injury depends on the agents administered, 
while the degree of hepatotoxicity is related to duration of therapy, as well as the 
chemotherapeutic agents used. 
Steatosis was one of the first lesions observed in association with chemotherapy. In a 
phase II clinical trial where irinotecan-based chemotherapy was administered prior to 
surgery, we observed that 66% of patients had hepatic steatosis (Bathe et al., 2009). Others 
have observed lower rates of steatosis, ranging from 9 – 30% (Vauthey et al., 2006). This 
large range may be due to differences in definitions or severity of steatosis, as well as to 
population-specific factors such as incidence of diabetes and obesity. Vauthey et al. (2006) 
reported that no specific chemotherapy regimen was particularly associated with 
steatosis. However, steatohepatitis, which involves a monomorphic and neutrophilic 
inflammatory response in addition to steatosis, occurs in a minority of individuals, and it 
is particularly associated with exposure to irinotecan containing regimens—20.2% vs. 
4.2% with no chemotherapy (Vauthey et al., 2006).  
Vascular changes including hepatic sinusoidal dilatation, peliosis, hemorrhagic centrilobular 
necrosis and regenerative nodular hyperplasia have also been observed. These lesions are 
particularly common in individuals who have received oxaliplatin-based regimens (Aloia et 
al., 2006b; Kandutsch et al., 2008; Karoui et al., 2006; Vauthey et al., 2006). Sinusoidal 
congestion and dilatation is present in 18 –23% of individuals who have had oxaliplatin 
(Aloia et al., 2006b; Vauthey et al., 2006; Wicherts et al., 2011a). Regenerative nodules appear 
in individuals who have had a prolonged exposure to chemotherapy, and they appear to 
represent an end-stage vascular injury (Aloia et al., 2006b; Wicherts et al., 2011a). 
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The effects of each of these lesions on liver function and clinical outcomes following liver 
resection vary. Steatosis has been associated with an increase in postoperative morbidity 
although mortality rates do not appear to be adversely affected (Belghiti et al., 1998; Kooby 
et al., 2003). Steatohepatitis is clearly associated with increased mortality. In the series 
described by Vauthey and colleagues, steatohepatitis was associated with a 90-day mortality 
rate of 14.7%, whereas the mortality was only 1.6% in individuals without steatohepatitis 
(2006). The impact of sinusoidal dilatation and other vascular injuries from chemotherapy 
on operative outcomes is not clear. In a number of series, sinusoidal dilatation was not 
associated with increased morbidity and mortality following liver resection (Kishi et al., 
2010; Nordlinger et al., 2008; Kandutsch et al., 2008; Vauthey et al., 2006). However, the 
more severe vascular lesions, such as hemorrhagic centrilobular necrosis and regenerative 
nodular hyperplasia, may be associated with increased transfusion requirements and liver 
dysfunction (Aloia et al., 2006b; Wicherts et al., 2011a). The influence of chemotherapy on 
operative morbidity is proportional to the duration of neoadjuvant chemotherapy (Aloia et 
al., 2006b; Karoui et al., 2006; Kishi et al., 2010). This has led to a general recommendation to 
limit the degree of exposure to chemotherapy in the preoperative phase to a period of two to 
three months, if possible. In addition, lower morbidity rates have been reported when liver 
resection is performed more than 4 weeks after stopping chemotherapy (Welsh et al., 2007).  
There is evidence that some of the biological agents modify the degree of hepatic injury 
induced by cytotoxic agents. In one report, the prevalence of sinusoidal injury and fibrosis 
was lower in patients who received cetuximab, and the prevalence of steatohepatitis was 
lower in patients who received bevacizumab (Pessaux et al., 2010). The addition of 
bevacizumab or cetuximab to neoadjuvant chemotherapy did not appear to increase the 
morbidity rates after hepatectomy, and was not associated with any additional 
histopathologic evidence of hepatic injury. In individuals exposed to 5-FU and oxaliplatin, 
bevacizumab appears to diminish the incidence and severity of sinusoidal dilatation 
(Klinger et al., 2009; Ribero et al., 2007). Bevacizumab does not appear to adversely affect 
postoperative liver function (Wicherts et al., 2011b), but the effects of cetuximab on liver 
function require further study. 
6.2 Thromboembolic complications 
Any systemic therapy regimen that increases the risk for thromboembolic complications 
should be viewed with caution when administered in the preoperative setting. 
Thromboembolic events that occur preoperatively may delay surgery, and patients on 
anticoagulants will have an increased risk of bleeding from liver resection. 
In our own experience, individuals who had irinotecan-based neoadjuvant chemotherapy 
had a particularly high risk of thromboembolic complications. Significant thromboembolic 
events have previously been reported with irinotecan and bolus 5-FU/leucovorin (Pan et al., 
2005; Rothenberg et al., 2001). Another study utilizing a similar chemotherapy regimen prior 
to liver resection did not demonstrate such a high thromboembolic event rate (Pozzo et al., 
2004). Therefore it is difficult to determine whether the chemotherapy itself represents a risk 
factor for thromboembolic complications. A number of contributory risk factors are also 
present in this patient population in addition to the underlying malignancy. In particular, 
the insertion of indwelling central venous catheters can be associated with increased risk of 
thromboembolic complications (Seddighzadeh, Shetty, & Goldhaber, 2007). Given the 
spurious nature of reports on thromboembolic complications in irinotecan-containing 
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neoadjuvant chemotherapy regimens, it is premature to completely dismiss their role in the 
management of colorectal liver metastases. 
Bevacizumab is also associated with a risk of thromboembolic complications including 
arterial thrombosis (Kozloff et al., 2010; Schutz et al., 2010). Therefore, caution should be 
utilized when using bevacizumab containing regimens in the preoperative setting. Having 
said this, a number of series have been reported in which preoperative bevacizumab was 
not associated with a particularly high rate of thromboembolic complications, and surgery 
done more than 8 weeks after the last dose of bevacizumab was considered safe 
(Gruenberger et al., 2008b; Wicherts et al., 2011b). 
6.3 Planning the liver resection following a significant response to chemotherapy 
In this chapter we have already shown that unresectable tumors can be downstaged with 
chemotherapy to a point where they are rendered resectable. However, the question 
remains whether it is oncologically appropriate to remove less leiver in the case of liver 
metastases that have shrunk with chemotherapy. A liver-sparing approach would be 
adequate if the metastasis shrank in a concentric fashion. However, if intratumoral cell 
death from chemotherapy had a more random distribution, then doing a liver-sparing 
resection may result in leaving islands of viable tumor in the space previously occupied 
by the tumor. 
Our group studied the histologic patterns of response to chemotherapy to define whether 
lesions actually shrank in a centripetal fashion (Ng et al, 2008). Our detailed histopathologic 
analysis demonstrated that tumor did indeed shrink centripedally. However, there were 
also regional differences in the degree of chemotherapy-induced cell death and fibrosis, 
resulting in the appearance of islands of viable tumor outside of the confines of the main 
tumor. Fortunately, these islands of viable tumor always resided close to the gross residual 
tumor. These observations provided support to the practice of removing only the residual 
tumor (and possibly preserving liver parenchyma), although a margin of > 1 cm might be 
desirable to avoid leaving behind more peripheral islands of viable tumor. 
6.4 Management of a complete response to chemotherapy 
Management of patients who have sustained a complete response to chemotherapy is also 
controversial. A series of 15 patients with complete radiographic response to chemotherapy 
was reported by Elias et al. (2004). All were submitted to surgery. In four patients, the 
lesions could be found at laparotomy, and were therefore resected. In the other 11 patients, 
the site of liver metastases could not be found at the time of laparotomy and were therefore 
left in situ. Three of these lesions eventually recurred within a median follow-up of 31.3 
months. Benoist and colleagues reported another series of 66 patients with complete 
disappearance of metastases on CT. Thirty-one patients were observed. Within a year, 23 of 
these lesions reappeared on CT scan. Of the patients who went for surgery, 20 had 
macroscopically visible tumor at surgery, 15 had invisible metastases that were resected, 
and viable tumor cells were seen in 12 of the final pathologic specimens (Benoist et al., 2006). 
These observations suggest that, in the majority of individuals who have experienced a 
radiographic complete response to chemotherapy, residual tumor is present. Therefore, 
there is a rationale to remove all segments of liver in which tumor had resided prior to 
chemotherapy. Alternatively, patients can be treated expectantly with extremely close 
follow-up, and ablative treatments can be administered as soon as tumor recurs. 
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6.5 Response as a prognostic marker 
One rationale for neoadjuvant chemotherapy is that it is utilized as a means of selecting 
patients for resection. In particular, if extrahepatic disease appears during preoperative 
chemotherapy, then it is not likely that the patient will benefit from hepatic metastasectomy.  
Clinical management is not as well defined in patients who experience disease progression 
while on chemotherapy yet who still have resectable disease confined to the liver. Most data 
suggest that progression on chemotherapy is associated with a worse prognosis. A large 
retrospective series reported by Adam and coworkers demonstrated that patients who 
progressed on chemotherapy prior to liver resection had a 5-year overall survival and disease-
free survival of only 8% and 3%, respectively (Adam et al., 2004). Similarly, Gruenberger’s 
group reported a median recurrence-free survival of 24.7 months in patients who had a 
response to chemotherapy, 8.2 months in patients who had stable disease, and only 3.0 months 
in patients who had progressive disease (Gruenberger et al., 2008a). Others have also 
demonstrated the prognostic value of response to chemotherapy (Chan et al., 2010; Small et al., 
2009). These observations have prompted reflection on whether individuals who have 
progressed on chemotherapy should be considered candidates for liver resection. On the other 
hand, some have observed that response to chemotherapy is not prognostic in certain 
circumstances, such as in synchronous metastases (Gallagher et al., 2009). Moreover, it is not 
clear whether resection could still provide some clinical advantage in those patients with 
progression. More research is required to determine the best treatment algorithm for patients 
who have progressed on chemotherapy yet still have technically resectable disease. 
6.6 The need for a working multidisciplinary tumor conference  
If neoadjuvant chemotherapy is to be considered in the management of colorectal liver 
metastases, then a coordinated and well-functioning multidisciplinary group is essential. It 
begins with review of imaging by a radiologist with specialty in the area. In consultation 
with the surgical team, a decision on resectability should be made from initial imaging. This 
stratifies the patient into: unresectable/pallative treatment; unresectable but suitable for 
chemotherapy in an attempt at conversion to resectable status; and resectable at 
presentation. With this information, the medical oncologist is given clear goals for treatment 
and an appropriate systemic regimen is chosen. It is important that the medical oncologist 
understands the concerns of the surgeon with respect to the potential hepatotoxicity of any 
chemotherapy, and the need to limit the course of treatment to only that which is necessary 
in the neoadjuvant setting. Administration of drugs such as bevacizumab in the 
perioperative period is also concerning and further highlights the need to coordinate the 
timing of chemotherapy and surgery. The surgeon should have a role in ongoing 
monitoring of patients undergoing a “conversion to resectable” approach in order to decide 
when the patient has reached a resectable state. The role of an experienced liver surgeon, as 
well as medical oncologist and others, in the delivery of care cannot be overemphasized. 
This approach to care has been endorsed by the National Comprehensive Cancer Network 
and others (NCCN, 2011; Vickers et al., 2010). 
7. Future considerations 
The administration of chemotherapy prior to resection of liver metastases is gaining 
popularity. There are a number advantages to this approach but there are also some 
disadvantages, as we have outlined in this article. Trials will be required, trials will be 
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required that compare outcomes related to preoperative or perioperative chemotherapy versus 
postoperative chemotherapy. The design of these trials will be particularly important and will 
require some forethought. For example, there are some agents, such as bevacizumab and 
irinotecan, that are unlikely to be successful in an adjuvant setting given results from adjuvant 
trials in the non-metastatic setting (Saltz et al., 2007; Allegra et al., 2011). More research is 
required to understand the underlying cause of hepatotoxicity associated with certain 
chemotherapy agents. Understanding the mechanisms of hepatotoxicity may aid in 
developing strategies to reduce it, and ultimately enhance the safety of liver resection 
following chemotherapy. As biological or targeted therapies become more frequently utilized, 
it may be that current criteria for measuring response (Response Evaluation Criteria In Solid 
Tumors; RECIST) are insufficient to determine whether there is a benefit to any chemotherapy. 
This is due to the phenomenon that many of these agents induce more of a cytostatic rather 
than cytocidal response. Therefore, new methods of determining biological response 
(including the use of biomarkers and metabolic measures such as PET) will have to be 
investigated when gauging response. Eventually biomarkers will be developed to predict the 
likelihood of response to a particular chemotherapy and the identification of such biomarkers 
would result in truly personalized cancer care. Furthermore, prognostic biomarkers would 
help to select patients who would most likely benefit from surgery. Ultimately a combination 
of predictive and prognostic biomarkers would be very useful for this field and will constitute 
an important part of decision-making in the future. 
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The most significant advances in cancer therapy in recent years have involved the development of systemic
therapeutics. With improvements in response rates in solid tumors, opportunities have arisen to enhance the
effectiveness of surgery. Administration of systemic therapy prior to surgery - neoadjuvant chemotherapy -
represents one approach by which clinicians have successfully reduced the extent of surgery and, in some
instances, positively impacted on clinical outcomes. This collection of works by expert clinicians from a variety
of disciplines represents an exploration of the current knowledge of the role of neoadjuvant chemotherapy in
diverse tumor types.
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